87 related articles for article (PubMed ID: 21592317)
1. Melanoma researchers have a reason to GRIN: melanoma yields more of its secrets to exome sequencing.
Meltzer P
Pigment Cell Melanoma Res; 2011 Aug; 24(4):590-1. PubMed ID: 21592317
[No Abstract] [Full Text] [Related]
2. MITF pathway mutations in melanoma.
Yokoyama S; Salma N; Fisher DE
Pigment Cell Melanoma Res; 2009 Aug; 22(4):376-7. PubMed ID: 19558635
[No Abstract] [Full Text] [Related]
3. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
[TBL] [Abstract][Full Text] [Related]
5. Exome sequencing identifies GRIN2A as frequently mutated in melanoma.
Wei X; Walia V; Lin JC; Teer JK; Prickett TD; Gartner J; Davis S; ; Stemke-Hale K; Davies MA; Gershenwald JE; Robinson W; Robinson S; Rosenberg SA; Samuels Y
Nat Genet; 2011 May; 43(5):442-6. PubMed ID: 21499247
[TBL] [Abstract][Full Text] [Related]
6. Identification of new genes associated with melanoma.
Mauerer A; Roesch A; Hafner C; Stempfl T; Wild P; Meyer S; Landthaler M; Vogt T
Exp Dermatol; 2011 Jun; 20(6):502-7. PubMed ID: 21410771
[TBL] [Abstract][Full Text] [Related]
7. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.
Fujimoto A; Morita R; Hatta N; Takehara K; Takata M
Oncogene; 1999 Apr; 18(15):2527-32. PubMed ID: 10229204
[TBL] [Abstract][Full Text] [Related]
8. Association of galectin-3 expression with melanoma progression and prognosis.
Brown ER; Doig T; Anderson N; Brenn T; Doherty V; Xu Y; Bartlett JM; Smyth JF; Melton DW
Eur J Cancer; 2012 Apr; 48(6):865-74. PubMed ID: 22071132
[TBL] [Abstract][Full Text] [Related]
9. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
Gonzalgo ML; Bender CM; You EH; Glendening JM; Flores JF; Walker GJ; Hayward NK; Jones PA; Fountain JW
Cancer Res; 1997 Dec; 57(23):5336-47. PubMed ID: 9393758
[TBL] [Abstract][Full Text] [Related]
10. Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36.
Poetsch M; Dittberner T; Woenckhaus C
Oncogene; 2002 May; 21(19):3038-42. PubMed ID: 12082534
[TBL] [Abstract][Full Text] [Related]
11. DNA damage and repair in melanoma and non-melanoma skin cancer.
Camplejohn RS
Cancer Surv; 1996; 26():193-206. PubMed ID: 8783574
[No Abstract] [Full Text] [Related]
12. [The DNA and sex chromatin in pigmented skin neoplasms in man].
Naleskina LA
Vopr Onkol; 1971; 17(4):8-14. PubMed ID: 5564886
[No Abstract] [Full Text] [Related]
13. The initiation and progression of melanoma: estrogens or estrogen receptors?
de Giorgi V; Gori A; Grazzini M; Rossari S; Sestini S; Mavilia C; Massi D; Brandi ML; Lotti T
Melanoma Res; 2010 Feb; 20(1):64-5. PubMed ID: 20051783
[No Abstract] [Full Text] [Related]
14. Carcinoma renegades. Why do tumors spread?
Tangley L
US News World Rep; 2000 Aug; 129(6):47. PubMed ID: 11010050
[No Abstract] [Full Text] [Related]
15. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.
Zerp SF; van Elsas A; Peltenburg LT; Schrier PI
Br J Cancer; 1999 Feb; 79(5-6):921-6. PubMed ID: 10070891
[TBL] [Abstract][Full Text] [Related]
16. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
Settleman J
Cancer Cell; 2009 Oct; 16(4):278-9. PubMed ID: 19800573
[TBL] [Abstract][Full Text] [Related]
17. Mutated ERBB4: a novel drug target in metastatic melanoma?
Kurppa K; Elenius K
Pigment Cell Melanoma Res; 2009 Dec; 22(6):708-10. PubMed ID: 19735458
[No Abstract] [Full Text] [Related]
18. Molecular biomarkers of prognosis in melanoma: how far are we from the clinic?
Schramm SJ; Menzies AM; Mann GJ
Melanoma Res; 2013 Dec; 23(6):423-5. PubMed ID: 24165033
[No Abstract] [Full Text] [Related]
19. Illuminating progression: tracking melanoma metastasis in a gene therapy setting.
Day CP; Merlino G
Pigment Cell Melanoma Res; 2011 Apr; 24(2):260-1. PubMed ID: 21226857
[No Abstract] [Full Text] [Related]
20. TTC4, a novel candidate tumor suppressor gene at 1p31 is often mutated in malignant melanoma of the skin.
Poetsch M; Dittberner T; Cowell JK; Woenckhaus C
Oncogene; 2000 Nov; 19(50):5817-20. PubMed ID: 11126369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
